Doses used in ARA-290 human trials Study context Sarcoidosis pilot (2012) Dose & route 2 mg IV Schedule 3x/week, 4 weeks Study context Sarcoidosis SFN (2013) Dose & route Daily subQ Schedule 28 days Study context Type 2 diabetes neuropathy (2014) Dose & route 4 mg subQ Schedule Daily, 28 days Study context Phase 2b sarcoidosis (2017) Dose & route 1, 4, or 8 mg subQ Schedule Daily, 28 days Study context Diabetic macular edema (2020) Dose & route 4 mg subQ Schedule Daily, 12 weeks This is trial reporting, not a dosing recommendation
Fertility and Sterility, 106(7), e251-e256
Peptides vs GLP-1 Drugs for Women Many women arrive already taking or considering a GLP-1 medication such as semaglutide or tirzepatide and want to know how peptides compare
These peptides stabilize menstrual cycles by affecting progesterone, estrogen, and inflammatory markers associated with cycle regularity, according to research